Table 1.
Groups of mice immunized with different formulations of monovalent SARS-CoV-2 RBD vaccines.
| Group # | Riboxxim™ (μg) | Chitosan (μg) | RBD (μg) | RBD-C-CPE (μg) |
|---|---|---|---|---|
| 1 | 50 | – | 10 | – |
| 2 | 50 | – | 10 | – |
| 3 | 50 | 10 | 10 | – |
| 4 | – | – | 10 | – |
| 5 | 50 | – | – | – |
| 6 | 50 | 10 | – | – |
| 7 | 50 | – | – | 10 |
| 8 | – | – | – | 10 |
| 9 (PBS) | – | – | – | – |
Nine groups of mice (n = 5 animals per group) were immunized with monovalent SARS-CoV-2 RBD vaccines of the indicated formulations. RBD-cCPE: receptor binding domain fused to the C-terminal polypeptide of the C. perfringens toxin (cCPE), which targets Claudin-4 on microfold (M) cells. Riboxxim™: Synthetic, double-stranded RNA TLR3/RIG-I agonist.